BioXcel Therapeutics Inc expected to post a loss of 70 cents a share - Earnings Preview

BioXcel Therapeutics

07/05/2024 17:59

* BioXcel Therapeutics Inc  BTAI.OQ   BTAI.O  is expected
to show
a rise in quarterly revenue when it reports  results on May 9
for the period ending March 31 2024
    * The New Haven Connecticut-based  company is expected to
report a
125.2% increase in revenue to $464 thousand from $206 thousand a
year ago, according to the mean estimate from 5 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for BioXcel Therapeutics Inc
is
for a loss of 70 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 0.1%
in the last three months. ​
    * Wall Street's median 12-month price target for BioXcel
Therapeutics Inc is $7.00​, above​ its last closing price
of $2.51. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.94       -0.91      -0.76     Beat    16.5
 Jan. 1 2023   -1.80       -1.30      -1.72     Missed  -31.9
 Jun. 30 2023  -1.80       -1.75      -1.83     Missed  -4.5​
 Mar. 31 2023  -1.81       -1.62      -1.84     Missed  -13.7
 ​​Jan.        -1.49       -1.45      -1.95     Missed  -34.8
 1 0001                                                 
 Jan. 1 0001   -1.33       -1.35      -1.49     Missed  -10.5​
 Jun. 30 2022  -1.23       -1.22      -1.35     Missed  -10.7
 Mar. 31 2022  -1.11       -1.15      -1.12     Beat    2.3
 This summary was machine generated May 7 at 16:59 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)